Yo, technology.

What is it all about?

So even for me as a happy person, it added so much of happiness and positivity.

So it was hands down the single most meaningful thing I've ever done in my whole life that I was literally the next day.

I was like, okay, I can totally see if it's doing this amount of

positivity to me as a healthy happy person I can totally see how this might be able to

cure and help people with mental health issues.

Hello. Hello and welcome to Danny in the Valley, your weekly dispatch from behind the scenes and inside the minds of the top people in tech.

Thank you for tuning in.

I am Danny Fortson, the West Coast correspondent for the Sunday Times and your host.

We have a great podcast for you this week, and it is all about psychedelics.

On the program to talk about it is Christian Engermeyer.

He is the founder of Atai Life Sciences, which recently went public on the NASDAQ at around $3 billion.

And a tie is just totally unique.

It is the world's largest and I'm pretty certain the only psychedelics company.

And what it has done over the past few years is really recast magic mushrooms, ketamine,

Ibogaine, these substances that are either classified

as Class A drugs or just illegal drugs, and really reposition them as potentially

breakthrough medicines for a whole range of mental health problems, most notably

treatment-resistant depression. They are all now in critical trials of various stages, including at Compass Pathways, which

ties a big investor in.

And Compass, of course, is the London-based developer of psilocybin-based treatments for

...